NGM Bio

NGM Bio is a clinical stage biopharmaceutical company that develops biologic drugs for the treatment of cardio-metabolic and liver disease. Read more

221 Followers on Owler
221 Followers on Owler
221 Followers on Owler
221 Followers on Owler

NGM Bio

NGM Bio is a clinical stage biopharmaceutical company that develops biologic drugs for the treatment of cardio-metabolic and liver disease. Read more

David J. Woodhouse's photo - CEO of NGM Bio

CEO

David J. Woodhouse

CEO Approval Rating

89/100

Founded:

2008

Status:

PublicIndependent CompanyNASDAQNGM

NGM BIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

ARMO BioSciences is NGM Bio's #1 competitor. ARMO BioSciences's headquarters is in Redwood City, California, and was founded in 2012. ARMO BioSciences competes in the Health Care Services industry. ARMO BioSciences generates 10% of NGM Bio's revenue.

Lixte is one of NGM Bio's top rivals. Lixte was founded in New York, New York} in 2006. Like NGM Bio, Lixte also works within the Pharmaceuticals sector. Compared to NGM Bio, Lixte generates $87.2M less revenue.

vTv Therapeutics is one of NGM Bio's top competitors. vTv Therapeutics is a Public company that was founded in 2015 in High Point, North Carolina. vTv Therapeutics operates in the Pharmaceuticals industry. Compared to NGM Bio, vTv Therapeutics has 184 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Petra Pharma a competitor of NGM Bio?

NGM Bio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$87.4M

NGM Bio's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 1.4B. Over the last four quarters, NGM Bio's revenue has decreased by 22.1%. Specifically, in Q4 2020's revenue was $44.1M; in Q3 2020, it was $23.5M; in Q2 2020, it was $19.8M; in Q4 2019, NGM Bio's revenue was $56.6M.

NGM Bio Acquisitions

No recent acquisitions found related to NGM Bio

NGM Bio Funding History

Since NGM Bio was founded in 2008, it has participated in 6 rounds of funding. In total NGM Bio has raised $344.8M. NGM Bio's last funding round was on Apr 2019 for a total of $122.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2019
$122.7M

Series E
Mar 2015
$106M
-
Series D
Oct 2014
$20.7M
Series C
Apr 2013
$13.5M
Equity
Mar 2010
$55.4M
-

Since NGM Bio was founded in 2008, it has participated in 6 rounds of funding. In total NGM Bio has raised $344.8M. NGM Bio's last funding round was on Apr 2019 for a total of $122.7M

NGM Bio Investments

No recent investments found related to NGM Bio

NGM Bio News

March 6, 2021News Break

NGM Biopharmaceuticals (NASDAQ:NGM) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS | News Break

NGM Biopharmaceuticals (NASDAQ:NGM) announced its quarterly earnings data on Wednesday. The company r... See more »
March 4, 2021Markets Insider

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results

•Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fo... See more »
January 12, 2021MarketScreener

NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology

(marketscreener.com) NGM advances its vision to build the next iconic biologics company, fueled by it... See more »
January 6, 2021BioSpace

NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transform... See more »
December 16, 2020Zolmax News

NGM Biopharmaceuticals, Inc. to Post Q1 2021 Earnings of ($0.45) Per Share, B. Riley Forecasts (NYSE:NGM)

NGM Biopharmaceuticals, Inc. (NYSE:NGM) - Equities researchers at B. Riley issued their Q1 2021 EPS e... See more »
November 25, 2020Zolmax News

NGM Biopharmaceuticals (NYSE:NGM) Hits New 52-Week High at $24.24

Shares of NGM Biopharmaceuticals, Inc. (NYSE:NGM) reached a new 52-week high during mid-day trading o... See more »

NGM Bio Press Releases

December 9, 2020GlobeNewswire

NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Na... See more »
November 13, 2020GlobeNewswire

NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual

--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-... See more »
November 12, 2020GlobeNewswire

NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Na... See more »
November 11, 2020GlobeNewswire

NGM Bio to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Na... See more »
November 5, 2020GlobalNewswire

NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual

--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential... See more »
July 31, 2020StreetInsider

NGM Bio to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Na... See more »
June 8, 2020GlobeNewswire

NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Na... See more »

NGM Bio Videos

Social Media

NGM Bio Headquarters

333 Oyster Point Boulevard

South San Francisco, California94080

650-243-5555

Driving Directions »

Trending Companies

NGM Bio Summary

ABOUT

Overview

NGM Bio is a clinical stage biopharmaceutical company that develops biologic drugs for the treatment of cardio-metabolic and liver disease. NGM Bio was founded in 2008. NGM Bio's headquarters is located in South San Francisco, California, USA 94080. I...

CEO

NGM Bio's CEO, David J. Woodhouse, currently has an approval rating of 89%. NGM Bio's primary competitors are ARMO BioSciences, Lixte & vTv Therapeutics.

Website

ngmbio.com

Frequently Asked Questions about NGM Bio

  1. When was NGM Bio founded?

    NGM Bio was founded in 2008
  2. Who is NGM Bio's CEO?

    NGM Bio's CEO is David J. Woodhouse
  3. How much revenue does NGM Bio generate?

    NGM Bio generates $87.4M in revenue
  4. How much funding does NGM Bio have?

    NGM Bio has historically raised $344.8M in funding
  1. Where is NGM Bio's headquarters?

    NGM Bio's headquarters is in South San Francisco California, USA
  2. How many employees does NGM Bio have?

    NGM Bio has 210 employees
  3. What sector does NGM Bio operate in?

    NGM Bio is in Biotechnology, Pharmaceuticals
  4. Who are NGM Bio's competitors?

    NGM Bio's top competitors are ARMO BioSciences, Lixte, vTv Therapeutics